Fluocinonide
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
Fluocinonide: From Corticosteroid‑Responsive Dermatoses to Alopecia Mucinosa
One-Sentence Summary
Fluocinonide is a high-potency topical corticosteroid, established for inflammatory and pruritic corticosteroid-responsive dermatoses. The TxGNN model predicts it may be effective for Alopecia Mucinosa, but this is currently supported by 0 clinical trials and 0 publications — the signal comes from the prediction score alone.
Note: the evidence pack contains no original_indications or licence data for this drug, so the original-indication description above draws on established pharmacological knowledge of the fluocinonide class rather than the supplied dataset.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in the evidence pack (fluocinonide is generally used for corticosteroid-responsive inflammatory/pruritic dermatoses) |
| Predicted New Indication | Alopecia Mucinosa |
| TxGNN Prediction Score | 99.61% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for this drug in the evidence pack. Based on known information, fluocinonide is part of the topical corticosteroid (glucocorticoid receptor agonist) class, and its efficacy in corticosteroid-responsive inflammatory dermatoses has been proven; mechanistically, this class may be applicable to other inflammatory skin conditions.
Alopecia mucinosa (follicular mucinosis) is pathologically characterised by perifollicular lymphocytic infiltration and associated inflammation. In theory, the anti-inflammatory and immunomodulatory action of a potent corticosteroid such as fluocinonide could dampen this infiltrate, which is the mechanistic rationale offered for this prediction.
However, no clinical trial or published literature in this evidence pack directly links fluocinonide to alopecia mucinosa — the association rests entirely on the TxGNN model’s prediction score, without independent corroboration.
Note for reviewers: among the other candidates in this evidence pack, alopecia areata (rank 3, score 99.59%) has a more developed evidence base — one related clinical trial and one related publication — and a higher evidence level (L4 vs L5) and decision stage (S1 vs S0) than the top-ranked candidate above. It may warrant separate, closer evaluation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication (alopecia mucinosa) has no supporting clinical trials or literature — the evidence level is L5 (model prediction only) — and the drug currently has no UK marketing authorisation. There is insufficient basis to proceed.
To proceed, the following is needed:
- MHRA/SmPC warnings, contraindications and drug interaction data (currently a blocking data gap)
- Confirmed mechanism of action data from DrugBank or the SmPC
- Any clinical trial or literature evidence specific to fluocinonide in alopecia mucinosa
- Consideration of whether alopecia areata (rank 3), which has an existing trial and a related publication, is a more appropriate candidate for further evaluation
- Confirmation of original licensed indication(s) for fluocinonide, which were not present in this evidence pack
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.